IRIDEX Corp (IRIX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$0.68-0.35%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Intact: The reason to own it still holds.
IRIDEX aims for $51M-$53M revenue in 2026, showing growth potential. The company targets $19M-$19.5M operating expenses, aiming to control costs. Recent EPS beats despite revenue misses show improving execution. Cost reductions of $600,000 annually support profitability progress.
Revenue growth is slow and misses targets. The company remains loss-making with negative free cash flow. Cost control efforts may not offset weak sales growth.
The market expects about 9% revenue growth and values IRIDEX cheaply versus peers. Our fair value is near $8.03, reflecting cautious optimism on recovery.
Breaks if: EPS remains negative beyond FY27
Breaks if: Operating expenses exceed $19.5 million in FY26
Breaks if: Annual revenue falls below $51 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story. The company is working towards achieving cash flow positive operations while managing expenses, but it faces significant challenges in a high-risk sector.
The current valuation suggests that the market views IRIX as relatively cheap compared to its peers. However, there is a notable expectations gap, indicating that investors may have low confidence in the company's ability to meet its guidance.
Management is focused on achieving positive cash flow and has reaffirmed revenue guidance, though recent results show slight declines. The company is making progress on cash flow but is behind on controlling operating expenses.
The future performance of IRIX will depend on its ability to maintain guidance and control costs. Additionally, external factors such as sector performance and economic conditions will play a critical role.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company missed revenue and earnings estimates. This raises concerns about its annual revenue guidance. However, Cyclo G6 product sales grew, supporting expansion plans.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
The multi-year view on IRIX is cautious, given its mixed performance and high risk. Not investment advice.